Antibacterial and anti-biofilm activity of plumbagin against multi-drug resistant clinical bacterial isolates

Alfhili,M. A.,Ahmad,I.,Alraey,Y.,Alangari,A.,Alqahtani,T.,Dera,A. A.
DOI: https://doi.org/10.15537/smj.2022.43.11.20220446
2022-11-16
Saudi Medical Journal
Abstract:Objectives: To evaluate the antibacterial activity of plumbagin (PGN) against multidrug resistance (MDR) clinical isolates. Methods: This study was carried out at the Department of Clinical Lab Sciences, King Khalid University from October 6, 2021 to December 14, 2021. We investigated the antibacterial and anti-virulence activity of PGN against MDR Gram-negative ( Escherichia coli , Klebsiella pneumoniae , Salmonella Typhi , and Pseudomonas aeruginosa ) and Gram-positive ( Staphylococcus aureus [S. aureus] , Staphylococcus saprophyticus [S. saprophyticus] , Streptococcus pyogenes , and Enterococcus faecalis ) clinical bacterial isolates. Agar well diffusion, microdilution assay, colony count method, biofilm formation, and time-kill kinetics were employed to probe the MIC, MBC, and anti-virulence activity of PGN. Results: Plumbagin inhibited the growth of all tested isolates, with S. saprophyticus exhibiting the highest sensitivity. MIC values ranged from 0.029 to 0.117 μg/mL whereas MBC ranged from 0.235 to 0.94 μg/mL, with 79% to 99% growth inhibition. Moreover, all tested isolates showed a marked decrease in biofilm formation, with S. saprophyticus and S. aureus being the most sensitive. Conclusion: Plumbagin is a stand-alone, broad spectrum antibacterial with promising potential against the rising threat of antimicrobial resistance.
medicine, general & internal
What problem does this paper attempt to address?